EQ NASDAQ
Credit Risk of going bust: higher than 57% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down 99.8%), Equillium, Inc. would be worth roughly what it owes.
Total debt $584K against a stock market value of $79.3M.
Distance to default 4.46 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $498K (short-term plus half of long-term), stock volatility 103.5%; Altman Z'' 13.72. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
La Jolla, CA 92037
US
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Zedelmayer Christine | M-Exempt | 14,584 | $0.79 | 2026-06-05 |
| Zedelmayer Christine | S-Sale | 14,584 | $2.93 | 2026-06-05 |
| Zedelmayer Christine | M-Exempt | 14,584 | $0.79 | 2026-06-05 |
| Connelly Stephen | S-Sale | 30,975 | $2.94 | 2026-06-05 |
| Connelly Stephen | S-Sale | 200,000 | $3.16 | 2026-06-04 |